Hikma Pharmaceuticals (HIK)

 

HIK Share PerformanceMore

52 week high2,703.0 02/08/16
52 week low1,573.0 19/05/17
52 week change -650.0 (-29.02%)
4 week volume13,895,909 30/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

The week ahead: Big day for Sirius Minerals

The FTSE reshuffle takes effect Monday, while investors get an update from a retailer just days after grim retail sales data...

Director/PDMR Shareholding

RNS Number: 8588H Hikma Pharmaceuticals Plc 12 June 2017 Hikma Pharmaceuticals PLC - Vesting of LTIP LONDON, 12 June 2017: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (" Hikma ") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility (" PDMR ") have received shares as a result of th...

Total Voting Rights

RNS Number: 0731H Hikma Pharmaceuticals Plc 02 June 2017 Hikma Pharmaceuticals PLC Total Voting Rights and Capital LONDON, 2 June 2017, Hikma Pharmaceuticals PLC (LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 240,545,322 ordinary shares with voting rights. There are nil shares held in treas...

Director Deals - Hikma Pharmaceuticals PLC (HIK)

Said Darwazah, Chairman, has transferred in 52,164 shares in the company on the 29th May 2017 at a price of 0.00p. The D...

Director Deals - Hikma Pharmaceuticals PLC (HIK)

Mazen Darwazah, Executive Director, has transferred in 38,088 shares in the company on the 29th May 2017 at a price of 0...

Director/PDMR Shareholding

RNS Number: 6828G Hikma Pharmaceuticals Plc 31 May 2017 Hikma Pharmaceuticals PLC - Vesting of LTIP Awards LONDON, 31 May 2017: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (" Hikma ") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility (" PDMR ") have received shares as a re...

Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut it...

Broker Forecast - Cantor Fitzgerald issues a broker note on Hikma Pharmaceuticals PLC

Cantor Fitzgerald today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price ...

Fundamental DataMore

P/E ratio23.91
EPS66.5
Dividend yield2.075 %

Latest discussion posts More

  • AGM tomorrow

    May elaborate on the reasons for FDA rejection despite HIk being very confident of approval & revenue flows from the second half of this year.
    18-May-2017
    dave297
  • Ouch

    Looks like a basic schoolboy error. Or do the FDA have another ax to grind? Does not inspire confidence, they should have got this sorted out.
    12-May-2017
    Ravinell
  • Ouch

    Nasty reaction to the FDA news; but I think it's overdone. Basically it means Hikma won't be earning any money from a product in a market where it has never earned any money. ...
    11-May-2017
    Hardboy

Users' HoldingsMore

Users who hold Hikma Pharmaceuticals also hold..
LLOYDS GRP.32%
BT GROUP25%
GLAXOSMITHKLINE24%
BP24%
RDS 'B'24%

Codes & Symbols

ISINGB00B0LCW083
SymbolsHIK, LSE:HIK, HIK.L, HIK:LN, LON:HIK, XLON:HIK